The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

Authors: Appelbaum, Frederick R.1; Kopecky, Kenneth J.1; Tallman, Martin S.2; Slovak, Marilyn L.3; Gundacker, Holly M.1; Kim, Haesook T.4; Dewald, Gordon W.5; Kantarjian, Hagop M.6; Pierce, Sherry R.6; Estey, Elihu H.6

Source: British Journal of Haematology, Volume 135, Number 2, October 2006 , pp. 165-173(9)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Summary

To better understand the spectrum of adult acute myeloid leukaemia (AML) associated with core binding factor (CBF) translocations, 370 patients with newly diagnosed CBF-associated AML were analysed. Patients' age ranged from 16-83 years (median 39 years) with a slight male predominance (55%); 53% had inv(16); 47% had t(8;21). Patients with t(8;21) tended to be younger (P = 0·056), have lower peripheral blood white cell counts (P < 0·0001) and were more likely to have additional cytogenetic abnormalities (P < 0·0001). Loss of sex chromosome, del(9q) and complex abnormalities were more common among patients with t(8;21), while +22 and +21 were more common with inv(16). Overall, 87% [95% confidence interval (CI) 83-90%] of patients achieved complete response (CR) with no difference between t(8;21) and inv(16); however, the CR rate was lower in older patients due to increased resistant disease and early deaths. Ten-year overall survival (OS) was 44% (95% CI 39-50%) and, in multivariate analysis, was shorter with increasing age (P < 0·0001), increased peripheral blast percentage (P = 0·0006), in patients with complex cytogenetic abnormalities in addition to the CBF translocation (P = 0·021), and in patients with t(8;21) (P = 0·025). OS was superior in patients who received regimens with high-dose cytarabine, a combination of fludarabine and intermediate-dose cytarabine, or haematopoietic cell transplantation.

Keywords: acute myeloid leukaemia; core binding factor leukaemia; cytogenetics of leukaemia; leukaemia treatment; adult leukaemia

Document Type: Research article

DOI: 10.1111/j.1365-2141.2006.06276.x

Affiliations: 1: Southwest Oncology Group Statistical Center, Seattle, WA 2: Northwestern University Feinberg School of Medicine, Chicago, IL 3: City of Hope National Medical Center, Duarte, CA 4: Dana-Farber Cancer Institute, Boston, MA 5: Mayo Clinic, Rochester, MN 6: M.D. Anderson Cancer Center, Houston, TX, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A